论文部分内容阅读
目的观察ＣＭＣＶ方案与ＥＰ方案治疗非小细胞肺癌的疗效和毒副作用。方法采用随机分组的方法，将１９９２年１０月至１９９４年１２月住院的晚期非小细胞肺癌患者３１例，分为２组，即ＣＭＣＶ方案组和ＥＰ方案组，观察其疗效及其毒副作用。结果２组均无完全缓解病例，部分缓解率分别为５０．０％（８／１６）和５３．３％（８／１５），中位数生存期分别为１１．５月和１１．０月；两者无显著性差异。但白细胞下降和恶心呕吐ＥＰ方案较为严重（Ｐ＜０．０５）。结论不含顺铂的方案（ＣＭＣＶ方案）效果不低于ＥＰ方案，毒性较低，且经济方便，是目前治疗非小细胞肺癌的较理想方案
Objective To observe the efficacy and toxic side effects of CMCV and EP regimen in the treatment of non-small cell lung cancer. Methods Randomized grouping was used. Thirty-one patients with advanced non-small cell lung cancer who were hospitalized from October 1992 to December 1994 were divided into two groups: CMCV group and EP group. The efficacy and side effects were observed. Results There was no complete remission in the two groups. Partial remission rates were 50.0% (8/16) and 53.3% (8/15), respectively. The median survival time was 11.5 months and 11.0 months, respectively. There is no significant difference between the two. However, the decline of white blood cells and nausea and vomiting EP program is more serious (P <0.05). Conclusion The regimen containing no cisplatin (CMCV regimen) is no less effective than the EP regimen. It is less toxic and economically convenient. It is an ideal alternative for the treatment of non-small cell lung cancer.